The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial
The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial
复制标题
DOI：
10.1016/j.schres.2009.11.008
复制
发表时间：
2010-02-01
影响因子：
4.5
通讯作者：
Akhondzadeh, Shahin
中科院分区：
文献类型：
--
作者：
Abbasi, Seyed-Hesameddin;Behpournia, Haleh;Akhondzadeh, Shahin
据报道，米氮平有助于治疗精神分裂症的阴性症状。然而，到目前为止，结果是相互矛盾的。本研究采用随机双盲临床试验，观察米氮平与利培酮联合治疗慢性精神分裂症伴显著阴性症状患者的疗效。符合条件的研究参与者是40名慢性精神分裂症患者，年龄从19岁到49岁不等。所有患者都是住院患者，处于疾病活动期，符合DSM-IV-TR型精神分裂症标准。患者被随机分配到20例，利培酮6 mg/d加米氮平30 mg/d，20例利培酮6 mg/d加安慰剂。以阳性和阴性症状量表(PANSS)为主要评价指标。在为期8周的试验中，米氮平组在阴性症状和PANSS总分方面的改善明显更大。30 mg/d的米氮平治疗耐受性良好，未观察到临床重要的副作用。本研究表明，米氮平是一种潜在的联合治疗慢性精神分裂症的策略，特别是对阴性症状。(C)2009爱思唯尔B.V.保留所有权利。
It has been reported that mirtazapine would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of mirtazapine added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind and randomized clinical trial. Eligible participants in the study were 40 patients with chronic schizophrenia with ages ranging from 19 to 49 years. All patients were inpatients and were in the active phase of the illness, and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion 20 to risperidone 6 mg/day plus mirtazapine 30 mg/day and 20 to risperidone 6 mg/day plus placebo. The principal measure of the outcome was Positive and Negative Syndrome Scale (PANSS). The mirtazapine group had significantly greater improvement in the negative symptoms and PANSS total scores over the eight-week trial. Therapy with 30 mg/day of mirtazapine was well tolerated and no clinically important side effects were observed. The present study indicates mirtazapine as a potential combination treatment strategy for chronic schizophrenia particularly for negative symptoms. (C) 2009 Elsevier B.V. All rights reserved.